Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients
The main objective study is to compare the use of the cryoSPHERE probe to the standard-of-care method for pain management of patients receiving robotic-assisted thoracoscopic surgery, including reductions in opioid pain medication use and the development of post-surgical morbidity.
Checked against the public recordLast updated Mar 24, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- The Methodist Hospital Research Institute
- Interventions being studied
- Device: cryoSPHERE Ablation; Drug: Bupivacaine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Male and female patients 18-90 years of age * Diagnosis requiring robotic-assisted thoracoscopic surgery * Daily opioid use for at least 30 days consecutively at any point during the last 12 months prior to surgery or using opioids at the time of study enrollment * Experimental group only: agreement and consent to comply with all aspects of the study protocol and data collection, including follow-up contact. Exclusion Criteria: * Previous major surgery at the operative site (thoracotomy) * Allergy to aluminum * Allergy to plastics * Allergy to bupivacaine * Shingles disease * Demyelinating illnesses * Involvement with other interventional studies
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Houston Methodist Research InstituteHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 24, 2023. Always confirm current availability with the study team.